// App-Quantinova.ai

AB0220 (2021) : ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA) POSITIVITY IS ASSOCIATED WITH REDUCED WITHDRAWAL RATES OF ABATACEPT IN RHEUMATOID ARTHRITIS BUT ONLY IN PATIENTS WHO ARE ANTI-NUCLEAR ANTIBODY (ANA) NEGATIVE

Researchers

Presenter

  • J. Kimpton

Principal Investigators

  • M. Shipa

  • E. Hawkins

  • S. A. Yeoh

  • M. Greenwood

  • M. Ehrenstein

Medical Centers

  • University College London, Centre for Clinical Pharmacology and Therapeutics, London, United Kingdom

  • University College London, Gastroenterology, London, United Kingdom

  • University College London Hospital, GI Surgery Department, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved